Skip to content

Placement of Percutaneous Endoscopic Gastrostomy in Ambulatory Regimen in Selected Patients with Head and Neck Tumors: Feasibility and safety evaluation

Placement of Percutaneous Endoscopic Gastrostomy in Ambulatory Regimen in Selected Patients with Head and Neck Tumors: Feasibility and safety evaluation

Status
Not yet recruiting
Phases
Unknown
Study type
Interventional
Source
ANZCTR
Registry ID
ACTRN12618000696291
Enrollment
224
Registered
2018-04-30
Start date
2018-05-02
Completion date
2019-11-30
Last updated
2018-06-11

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

None listed

Brief summary

This study will allow to evaluate prospectivelly the possibility of outpatient PEG placement procedure in a cohort of patients with head and neck tumors with good status and low or moderate surgical anesthetic risk. PEG placement on outpatient basis will be helpful for patients, caregivers and the hospital.

Interventions

PEG placement is performed by two gastroenterologists under deep sedation performed by an anesthesiologist. The procedure takes about 15 minutes and it provides the patient a feeding tube conecting the gastric cavity to the outside for enteral nutrition. The ambulatory participant will be discharged without need for hospitalization 4 hours after the procedure. Oral analgesia for ambulatory (acetaminophen 1g every 8 hous, as needed) will be provided with a prescription provided by the gastroe

PEG placement is performed by two gastroenterologists under deep sedation performed by an anesthesiologist. The procedure takes about 15 minutes and it provides the patient a feeding tube conecting the gastric cavity to the outside for enteral nutrition. The ambulatory participant will be discharged without need for hospitalization 4 hours after the procedure. Oral analgesia for ambulatory (acetaminophen 1g every 8 hous, as needed) will be provided with a prescription provided by the gastroenterologist after patient evaluation, prior to discharge. The patient or a care-guiver will be responsible for oral analgesia administration.

Sponsors

Sandra Faias
Lead SponsorIndividual

Study design

Allocation
Randomised controlled trial
Intervention model
Parallel
Primary purpose
Treatment
Masking
Open (masking not used)

Eligibility

Sex/Gender
All
Age
18 Years to 80 Years
Healthy volunteers
No

Inclusion criteria

Patients with head and neck tumors referenced for PEG placement ASA Class <IV Performance Scale ECOG Status <3 Have quick access to the IPO Urgency (<1h by car) within 24 hours after the procedure. Have a caregiver within the first 24 hours after the procedure at your residence. Age> 18 years and <80 years Ability to provide informed consent

Exclusion criteria

Refusal of the patient Inability to provide informed consent Need for dilation prior to PEG placement Impossibility to access the IPO Urgency in the first 24 hours after the procedure in a period less than 1h Contraindications for PEG placement (patients unable to take PEG, chronic liver disease, presence of ascites, thrombocytopenia (<50,000 platelets), coagulopathy (INR> 1.5). Associated pathology: acute myocardial infarction and / or stroke for less than 1 year; severe tachyarrhythmia under treatment for less than 6 months; cardiac stent (s) placed for less than one year with a need for discontinuation of antiplatelet agents; severe renal insufficiency (creatinine greater than or equal to 2); severe respiratory insufficiency with SaO2 less than or equal to 90% without oxygen supply.

Outcome results

None listed

Source: ANZCTR · Data processed: Feb 4, 2026